Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation

Carcinogenesis

Volumn 30, Issue 2, 2009, Pages 348-355

  Huang, Jian ^a,b   Chen, Keqiang ^a   Huang, Jiaqiang ^c   Gong, Wanghua ^d   Dunlop, Nancy M ^a   Howard, O M Zack ^a   Bian, Xiuwu ^b   Gao, Yuqi ^b   Wang, Ji Ming ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c SuperArray Bioscience Corporation   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CELL SURFACE RECEPTOR; FORMYLPEPTIDE RECEPTOR; PROTEIN P53;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTAXIS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; METHYLATION; MOUSE; NONHUMAN; NUDE MOUSE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

ANIMALS; AZACITIDINE; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTAXIS; DNA MODIFICATION METHYLASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; METHYLATION; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; RECEPTORS, FORMYL PEPTIDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 60149095681     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn266     Document Type: Article

References (48)

1. Le,Y. et al. (2002) Formyl-peptide receptors revisited. Trends Immunol., 23, 541-548.
2. Cheng,N. et al. (2007) A critical role of protein kinase C delta activation loop phosphorylation in formyl-methionyl-leucyl-phenylalanine-induced phosphorylation of p47(phox) and rapid activation of nicotinamide adenine dinucleotide phosphate oxidase. J. Immunol., 179, 7720-7728.
3. Gao,J.L. et al. (1999) Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor. J. Exp. Med., 189, 657-662.
4. Rabiet,M.J. et al. (2005) Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur. J. Immunol., 35, 2486-2495.
5. Xia,S.H. et al. (2002) Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas. Oncogene, 21, 6641-6648.
6. Sun,R. et al. (2004) Identification of neutrophil granule protein cathepsin G as a novel chemotactic agonist for the G protein-coupled formyl peptide receptor. J. Immunol., 173, 428-436.
7. Rescher,U. et al. (2002) Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells. J. Immunol., 169, 1500-1504.
8. McCoy,R. et al. (1995) N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J. Exp. Med., 182, 207-217.
9. Liotta,L.A. et al. (2001) The microenvironment of the tumour-host interface. Nature, 411, 375-379.
10. Berens,M.E. et al. (1999) ".those left behind." Biology and oncology of invasive glioma cells. Neoplasia, 1, 208-219.
11. Huang,J. et al. (2008) G-protein coupled chemoattractant receptors and cancer. Front. Biosci., 13, 3352-3363.
12. Zhou,Y. et al. (2005) Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J. Natl Cancer Inst., 97, 823-835.
13. Huang,J. et al. (2008) Receptor "hijacking" by malignant glioma cells: A tactic for tumor progression. Cancer Lett., 267, 255-261.
14. Yao,X.H. et al. (2008) Production of angiogenic factors by human glioblastoma cells following activation of the G-protein coupled formylpeptide receptor FPR. J. Neurooncol., 86, 47-53.
15. Huang,J. et al. (2007) Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells. Cancer Res., 67, 5906-5913.
16. Le,Y. et al. (2000) Expression of functional formyl peptide receptors by human astrocytoma cell lines. J. Neuroimmunol., 111, 102-108.
17. Amatya,V.J. et al. (2005) TP53 promoter methylation in human gliomas. Acta Neuropathol., 110, 178-184.
18. Fruhwald,M.C. et al. (2001) Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - implications for tumor biology and potential clinical utility. Oncogene, 20, 5033-5042.
19. Michalowsky,L.A. et al. (1989) DNA methylation and differentiation. Environ. Health Perspect., 80, 189-197.
20. Kisseljova,N.P. et al. (2005) DNA demethylation and carcinogenesis. Biochemistry (Mosc.), 70, 743-752.
21. Shaker,S. et al. (2003) Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk. Res., 27, 437-444.
22. Shaker,S. et al. (2004) Antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells. Oncol. Rep., 11, 1253-1256.
23. Lemaire,M. et al. (2005) Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs, 16, 301-308.
24. Farinha,N.J. et al. (2004) Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2′-deoxycytidine (Decitabine). Anticancer Res., 24, 75-78.
25. Cameron,E.E. et al. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet., 21, 103-107.
26. Momparler,R.L. (2005) Pharmacology of 5-Aza-2′-deoxycytidine (decitabine). Semin. Hematol., 42, S9-S16.
27. Stiewe,T. (2007) The p53 family in differentiation and tumorigenesis. Nat. Rev. Cancer, 7, 165-168.
28. Ianzini,F. et al. (2007) Human glioblastoma U87MG cells transduced with a dominant negative p53 (TP53) adenovirus construct undergo radiation-induced mitotic catastrophe. Radiat. Res., 168, 183-192.
29. Van Meir,E.G. et al. (1994) Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res., 54, 649-652.
30. Bienz-Tadmor,B. et al. (1985) The 5′ region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J., 4, 3209-3213.
31. Schroeder,M. et al. (1997) CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem. Biophys. Res. Commun., 235, 403-406.
32. Radinsky,R. et al. (1994) Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene, 9, 1877-1883.
33. Feinstein,E. et al. (1992) Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene, 7, 1853-1857.
34. Shaulsky,G. et al. (1991) Involvement of wild-type p53 in pre-B-cell differentiation in vitro. Proc. Natl Acad. Sci. USA, 88, 8982-8986.
35. Kokunai,T. et al. (1997) Induction of differentiation by wild-type p53 gene in a human glioma cell line. J. Neurooncol., 32, 125-133.
36. Fridman,J.S. et al. (2003) Control of apoptosis by p53. Oncogene, 22, 9030-9040.
37. Kim,E. et al. (2003) Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene, 22, 7716-7727.
38. Sun,Y. et al. (2004) P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J. Cell. Biochem., 92, 258-269.
39. Mehta,S.A. et al. (2007) Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: Implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene, 26, 3329-3337.
40. Webster,G.A. et al. (1999) Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol., 19, 3485-3495.
41. Plesnila,N. et al. (2007) Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-kappaB transcriptional activity. Cell Death Differ., 14, 1529-1541.
42. Richmond,A. et al. (2004) How do chemokine/chemokine receptor activations affect tumorigenesis? Novartis Found. Symp., 256 74-89; (discussion 89-91, 106-111, 266-269).
43. Ueda,Y. et al. (2006) NF-kappaB activation in melanoma. Pigment Cell Res., 19, 112-124.
44. Yang,J. et al. (2007) Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res., 67, 3127-3134.
45. Dhawan,P. et al. (2008) The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J. Biol. Chem., 283, 15399-15408.
46. Inoue,J. et al. (2007) NF-kappaB activation in development and progression of cancer. Cancer Sci., 98, 268-274.
47. Sarkar,F.H. et al. (2008) NF-kappaB: A potential target for cancer chemoprevention and therapy. Front. Biosci., 13, 2950-2959.
48. Yan,B. et al. (2008) Systems biology-defined NF-kappaB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status. Genome Biol., 9, R53.